VALUE OF OTC MEDICINES IN EUROPE

22 November 1993

Whenever the value of the over-the-counter medicines market has to be criticized by a representative of the health insurance system the link between the prescription market and OTC moves to a central point of view, according to Karl-Heinz Schoenbach, director of the contract department at Germany's National Association of Company Sickness Funds.

Traditionally health insurers don't reimburse drugs that are not prescribed by a panel doctor, he told delegates at the recent World Federation of Pharmaceutical Manufacturers Federation meeting in Acapulco, Mexico (Marketletters November 8 and 15). But there are lots of problems in financing the increasing number of prescriptions written.

At present, Mr Schoenbach said, the scope of pharmaceutical cost containment strategies in Europe is wide, targeting not only price but other determinants of drug spending. Faced with further stress on their national health care budgets, governments and experts in European countries have concluded that, as a tool for restraining drug spending, controls on prices alone are not really sufficient.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight